美国12-17岁青少年接种新冠疫苗的安全性监测
VAERS收到9246份不良事件报告,其中90.7%为非严重事件,9.3%为严重事件,包括心肌炎(4.3%)。
要点
- VAERS报告以非严重不良事件为主(90.7%),严重事件占9.3%。
- 心肌炎报告占VAERS报告4.3%,主要见于年轻男性第二剂后。
- v-safe局部反应63.4%、全身反应48.9%,与临床试验相似。
核心结论
- 辉瑞-BioNTech新冠疫苗在12-17岁青少年中安全性与临床试验相似,心肌炎风险需继续监测。
研究设计与样本
- 对2020年12月14日至2021年7月16日VAERS被动监测和v-safe主动监测数据回顾分析。
主要发现
- VAERS报告中90.7%为非严重不良事件,9.3%为严重事件,其中心肌炎占4.3%。
- v-safe报告局部反应63.4%,全身反应48.9%,频率与授权前临床试验相似。
- 全身反应在第二剂后更常见。
临床怎么用
- CDC和FDA继续监测疫苗安全性并向ACIP提供数据以指导接种建议。
- ACIP于2021年6月23日评估数据后认为接种获益大于心肌炎风险,建议继续在≥12岁人群使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As of July 30, 2021, among the three COVID-19 vaccines authorized for use in the United States, only the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine is authorized for adolescents aged 12-17 years. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech vaccine for use in persons aged ≥16 years on December 11, 2020 (1); the EUA was expanded to include adolescents aged 12-15 years on May 10, 2021 (2), based on results from a Phase 3 clinical trial (3). Beginning in June 2021, cases of myocarditis and myopericarditis (hereafter, myocarditis) after receipt of Pfizer-BioNTech vaccine began to be reported, primarily among young males after receipt of the second dose (4,5). On June 23, 2021, CDC's Advisory Committee on Immunization Practices (ACIP) reviewed available data and concluded that the benefits of COVID-19 vaccination to individual persons and the population outweigh the risks for myocarditis and recommended continued use of the vaccine in persons aged ≥12 years (6). To further characterize safety of the vaccine, adverse events after receipt of Pfizer-BioNTech vaccine reported to the Vaccine Adverse Event Reporting System (VAERS) and adverse events and health impact assessments reported in v-safe (a smartphone-based safety surveillance system) were reviewed for U.S. adolescents aged 12-17 years during December 14, 2020-July 16, 2021. As of July 16, 2021, approximately 8.9 million U.S. adolescents aged 12-17 years had received Pfizer-BioNTech vaccine.* VAERS received 9,246 reports after Pfizer-BioNTech vaccination in this age group; 90.7% of these were for nonserious adverse events and 9.3% were for serious adverse events, including myocarditis (4.3%). Approximately 129,000 U.S. adolescents aged 12-17 years enrolled in v-safe after Pfizer-BioNTech vaccination; they reported local (63.4%) and systemic (48.9%) reactions with a frequency similar to that reported in preauthorization clinical trials. Systemic reactions were more common after dose 2. CDC and FDA continue to monitor vaccine safety and provide data to ACIP to guide COVID-19 vaccine recommendations.
引用
- Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34351881. doi:10.15585/mmwr.mm7031e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。